MedTrace Logo

Exploratory Study Of The ERCC-1 Gene

NCT00846482 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-09-16

Study results available
· View outcomes & findings →

Summary

This study is for patients with advanced or stage II and III colon or rectal cancer. The primary purpose of this research study is to determine if a particular protein in the patient's blood will change when they receive treatment with a drug called oxaliplatin, which is used to treat the colon or rectal cancer. This protein is called ERCC-1. It is thought that the amount of this protein in the blood could influence the manner in which the patient responds to oxaliplatin.

Conditions

Interventions

DRUG

Oxaliplatin

Oxaliplatin will be administered once every 2 or 3 weeks

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Albert Einstein College of Medicine

    lead OTHER

Principal Investigators

  • SANJAY GOEL, M.D. · Montefiore Medical Center/Albert Einstein College of Medicine

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846482 on ClinicalTrials.gov